Testosterone suppression by androgen deprivation therapy is the cornerstone of prostate cancer treatment. New-generation hormone therapies improved overall survival in castration-resistant prostate cancer. More recent trials showed a further increase in overall survival when enzalutamide or abiraterone are associated with androgen deprivation therapy in hormone-sensitive disease. However, a higher clonal pressure may lead to the upregulation of alternative pathways for cancer progression and to dedifferentiated diseases that would probably respond poorly to subsequent treatments. In this contest, new strategies that could be able to delay or even revert resistance are needed. The bipolar androgen therapy is an under-investigation treatment that consists in periodical oscillation between castration levels and supraphysiological levels of testosterone in order to prevent the adaptation of prostate cancer cells to a low-androgen environment. This review aims to underline the biological rationale of bipolar androgen therapy and gather evidences from the most recent clinical trials.

Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives

Leone G.;Buttigliero C.;Pisano C.;Di Stefano R. F.;Tabbo F.;Turco F.;Vignani F.;Scagliotti G. V.;Di Maio M.;Tucci M.
2020-01-01

Abstract

Testosterone suppression by androgen deprivation therapy is the cornerstone of prostate cancer treatment. New-generation hormone therapies improved overall survival in castration-resistant prostate cancer. More recent trials showed a further increase in overall survival when enzalutamide or abiraterone are associated with androgen deprivation therapy in hormone-sensitive disease. However, a higher clonal pressure may lead to the upregulation of alternative pathways for cancer progression and to dedifferentiated diseases that would probably respond poorly to subsequent treatments. In this contest, new strategies that could be able to delay or even revert resistance are needed. The bipolar androgen therapy is an under-investigation treatment that consists in periodical oscillation between castration levels and supraphysiological levels of testosterone in order to prevent the adaptation of prostate cancer cells to a low-androgen environment. This review aims to underline the biological rationale of bipolar androgen therapy and gather evidences from the most recent clinical trials.
2020
152
1
6
Androgen; Bipolar; Cancer; Prostate; Review; Therapy; Androgen Antagonists; Androgens; Humans; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen
Leone G.; Buttigliero C.; Pisano C.; Di Stefano R.F.; Tabbo F.; Turco F.; Vignani F.; Scagliotti G.V.; Di Maio M.; Tucci M.
File in questo prodotto:
File Dimensione Formato  
bipolar androgen therapy.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 180.01 kB
Formato Adobe PDF
180.01 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1769906
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact